On March 10, 2025, Mineralys Therapeutics announced positive results from its Phase 3 and Phase 2 trials for lorundrostat, showing significant reductions in blood pressure for patients with uncontrolled hypertension. The Launch-HTN trial involved 1,083 participants, achieving a placebo-adjusted reduction of -9.1 mmHg at week 6 and -11.7 mmHg at week 12, while the Advance-HTN trial showed a -7.9 mmHg reduction at week 12.